Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Cell Therapy Programs

New York – June 9, 2022 – Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on the expansion of its strategic alliance with Bristol Myers Squibb to pursue the development of multiple allogeneic off-the-shelf T cell receptor-based therapy (TCR-T) and/or chimeric antigen receptor (CAR-T) programs. Lawyers Kenneth Krisko, Alan Tamarelli, Brian Stalter, Stephanie Palmer, John Forrest and Carly Robinson led the Cooley team advising Immatics. 

Under the agreement, Immatics will receive an upfront payment of $60 million, as well as up to $700 million per the Bristol Myers Squibb program through development, regulatory and commercial milestone payments, and tiered royalty payments of up to low double-digit percentages on net product sales.

In addition, Bristol Myers Squibb and Immatics will expand their 2019 collaboration agreement focused on autologous TCR-T, with the inclusion of one additional TCR target discovered by Immatics, and the company will receive an upfront payment of $20 million, with eligibility for milestone payments and royalties.

Cooley previously advised Immatics on its global exclusive license agreement for its TCR bispecific candidate, IMA401, with Bristol Myers Squibb in December 2021.

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for Immatics’ pipeline of adoptive cell therapies and TCR bispecifics, as well as its partnerships with global leaders in the pharmaceutical industry. Immatics is committed to delivering the power of T cells and unlocking new avenues for patients in their fight against cancer.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 1,500 lawyers across 17 offices in the United States, Asia and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.